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esponsibility of Xi’Abstract A simple, rapid and sensitive ultra performance liquid chromatography-tandem mass
spectrometry (UPLC−MS/MS) method has been developed for the simultaneous determination of
cilostazol and its pharmacologically active metabolite 3,4-dehydro cilostazol in human plasma using
deuterated analogs as internal standards (ISs). Plasma samples were prepared using solid phase extraction
and chromatographic separation was performed on UPLC BEH C18 (50 mm 2.1 mm, 1.7 mm) column.
The method was established over a concentration range of 0.5–1000 ng/mL for cilostazol and 0.5–500 ng/
mL for 3,4-dehydro cilostazol. Intra- and inter-batch precision (% CV) and accuracy for the analytes were
found within 0.93–1.88 and 98.8–101.7% for cilostazol and 0.91–2.79 and 98.0–102.7% for the
metabolite respectively. The assay recovery was within 95–97% for both the analytes and internal
standards. The method was successfully applied to support a bioequivalence study of 100 mg cilostazol in
30 healthy subjects.
& 2014 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Peripheral arterial disease (PAD) is a common manifestation of
systemic atherosclerosis in which the blood vessels located outsidesity. Production and hosting by Elsev
1
6300969;
hoo.com (P.S. Shrivastav).
an Jiaotong University.the heart and brain are blocked or restricted. Intermittent claudication
(IC) is one of the early symptoms of PAD. IC is characterized by
stimulation of pain in leg muscles while walking relatively short
distances and relieve of pain on rest. Cilostazol (CIL), a selective
antagonist of phosphodiesterase (PDE) 3, was approved by US FDA
in 1999 for the treatment of IC [1]. The efﬁcacy of CIL for IC is
mainly attributed to its vasodilatory actions and antiplatelet activity.
Additionally, it shows antithrombotic effect, inhibits vascular smooth
muscle proliferation, increases high-density lipoprotein and reducesier B.V. All rights reserved.
N.M. Bhatt et al.2serum glycerides. Other beneﬁcial effects of CIL include endothelial
cell activation, neuroprotective activity and scavenging free radicals
[2]. CIL is an exceptional antiplatelet that shows minimal bleeding
risk, and unlike other PDE3 inhibitors, it can be used in patients
with cardiac comorbidities due to favorable effects on adenosine
uptake and plasma lipid proﬁle [3]. Most common adverse effects
reported on the use of CIL include headache, diarrhea and
palpitations. However, the symptoms are mild to moderate in
severity and rarely require discontinuation of the drug [4]. CIL is
rapidly absorbed after oral administration with a half life of 11–
13 h, with peak plasma concentration attained at 2–4 h after
administration. CIL is highly protein bound (95–98%) and is
extensively metabolized in the liver via the cytochrome P450
enzymes, with metabolites largely excreted in urine [4,5]. CIL has
been reported to metabolize to about 11 metabolites, among which
3,4-dehydro cilostazol (DCIL) is the major pharmacological active
metabolite [6].
Simultaneous determination of CIL and its active metabolites is
clinically important, especially DCIL, which is pharmacologically more
potent (ﬁve times) than the parent drug [4]. Several methods were
reported for the determination of CIL in biological ﬂuids. The ﬁrst
method was reported for the determination of CIL as a single analyte
in human plasma by reversed-phase HPLC [7]. Since then CIL was
determined in the presence of its metabolites in human plasma [8–10],
urine [11] and in liver microsomal incubation mixture [12] using either
HPLC [9,11,12] or LC-MS/MS [8,10]. Yeon et al. [13] presented an
automated microbore HPLC method with an on-line column switching
system to determine CIL in human plasma. Varanasi et al. [14]
developed and validated an LC-MS/MS method for simultaneous
quantiﬁcation of nateglinide, CIL, and DCIL in Wistar rat plasma. CIL
was also determined by luminescence spectroscopy using Tbþ3 as
optical sensor in human serum and urine samples [15].
To the best of our knowledge, there are no reports on the
simultaneous quantiﬁcation of CIL and DCIL by UPLC−MS/MS.
Thus, in the present work, a highly sensitive, rugged and rapid
UPLC−MS/MS method was developed and fully validated as per
the US FDA guidelines for the simultaneous estimation of CIL and
DCIL in human plasma using deuterated internal standards. The
method offered small turnaround time for analysis (1.2 min) and
high sensitivity (0.5 ng/mL) for both the analytes and utilized only
100 mL human plasma for sample processing using solid phase
extraction (SPE). The method was free from endogenous matrix
interference and was successfully applied to a bioequivalence
study with 100 mg cilostazol tablets in healthy subjects. The
reproducibility in the measurement of subject samples was
demonstrated by reanalysis of 125 incurred samples.2. Experimental
2.1. Chemicals and materials
Reference standard of CIL (99.4%), CIL-d11 (99.3%), 3,4-
dehydro cilostazol (DCIL, 99.5%) and DCIL-d11 (99.1%) were
procured from Clearsynth Labs Pvt. Ltd. (Mumbai, India). HPLC
grade methanol and acetonitrile were obtained from Mallinckrodt
Baker, S.A.de C.V. (Estado de Mexico, Mexico). BioUltra grade
ammonium formate and LC-MS grade formic acid were purchased
from Sigma-Aldrich (St. Louis, MO, USA). LiChroSep DVB-HL
(30 mg, 1 cc) solid phase extraction cartridges were obtained from
Merck Specialties Pvt. Ltd. (Mumbai, India). Deionized water was
obtained from Milli-Q water puriﬁcation system from Millipore(Bangalore, India). Blank human plasma was procured from
Supratech Micropath (Ahmedabad, India) and was stored at
70 1C until use.
2.2. Chromatographic and mass detection conditions
Waters Acquity UPLC BEH C18 (50 mm 2.1 mm, 1.7 mm)
column maintained at 30 1C was used for chromatographic
separation of the analytes. Elution of analytes and ISs was carried
out using a mobile phase consisting of acetonitrile and 2.0 mM
ammonium formate, pH 5.0 adjusted with 0.1% formic acid
(80:20, v/v), delivered at a ﬂow rate of 0.35 mL/min. The pressure
of the system was maintained at 4500 psi. Quantitative determina-
tion was performed on Waters Quattro Premier XE (USA) triple
quadrupole mass spectrometer equipped with electro-spray
ionization (ESI) in the positive ionization mode. The main
working parameters of the mass spectrometer are presented in
Supplementary Table 1. MassLynx software version 4.1 was used
to control all parameters of UPLC and MS.
2.3. Calibration standards and quality control samples
The standard stock solutions of CIL (400 mg/mL) and DCIL
(200 mg/mL) were prepared by dissolving their requisite amounts
in methanol. Further, working solutions were prepared using
intermediate solutions of 200 and 20.0 mg/mL for CIL, 100 and
20.0 mg/mL for DCIL in methanol:water (50:50, v/v), respectively.
The details of calibration standards (CSs) and quality control
samples concentrations prepared by spiking of blank plasma with
working solutions are given in Table 1. Separate stock solutions of
the internal standards (100/50.0 mg/mL for CIL-d11/DCIL-d11)
were prepared by dissolving accurately known amounts of ISs in
methanol. Their working solutions were prepared from their stock
solutions in methanol:water (50:50, v/v) at 800/400 ng/mL con-
centration for CIL-d11/DCIL-d11. Standard stock and working
solutions used for spiking were stored at 5 1C, while CSs and QC
samples in plasma were kept at 70 1C until use.
2.4. Extraction procedure
To an aliquot of 100 mL plasma sample, 25 mL of internal standard
was added and vortexed for 10 s. Further, 100 mL of water was
added and vortex mixed for another 30 s. The samples were
centrifuged at 14,000g for 5 min at 10 1C and loaded on
LiChroSep DVB-HL (30 mg, 1 cc) cartridges, pre-conditioned
with 1.0 mL methanol followed by 1.0 mL of water. The samples
were washed with 1.0 mL of 10% (v/v) methanol, followed by
1.0 mL of water. Thereafter, the cartridges were dried for 1 min
under nitrogen (1.72 105 Pa) at 2.4 L/min ﬂow rate. Both the
analytes and ISs were eluted using 400 mL of acetonitrile into pre-
labeled vials, followed by evaporation to dryness. The dried
residue was reconstituted with 100 mL of mobile phase, brieﬂy
vortexed for 15 s and 10 mL was used for injection in the
chromatographic system using an autosampler.
2.5. Validation procedures
Selectivity of the method was assessed for potential matrix inter-
ferences in 10 batches of blank human plasma by extraction and
inspection of the resulting chromatograms for interfering peaks. The
batches comprised 6 normal lots of K3EDTA, 2 haemolysed and 2
Table 1 Calibration standards, quality control samples and assay performance of the proposed method.
Proposed method Parameters Cilostazol 3,4-dehydro cilostazol
Linearity assessment (calibration
standards and quality control samples)
Linearity range (ng/mL) 0.5–1000 0.5–500
Calibration standards (ng/mL) 0.50, 1.00, 3.00, 10.0, 20.0,
40.0, 100, 200, 500 and 1000
0.50, 1.00, 5.00, 20.0, 50.0,
100, 200, 300, 400 and 500
Quality control samples (ng/mL) 0.50, 1.50, 150, 400 and 800 0.50, 1.50, 80.0, 200 and 420
Weighting factor 1/x2 1/x2
Mean regression line (y¼mxþc) y¼ (0.00252170.000019) xþ
(0.00003270.000005)
y¼ (0.00496670.000093) xþ
(0.00008770.000038)
Correlation coefﬁcient (r2) 0.9998 0.9994
Precision (% CV) 0.49–1.82 1.25–2.87
Accuracy (% ) 98.7–101.3 97.8–101.8
LLOQ and LOD (ng/mL; S/N ratio) 0.50; Z35 and 0.17; Z13 0.50; Z30 and 0.17; Z10
Assay performance System suitabilitya:
Precision (% CV) 0.35/ 0.84 for retention
time/area response
0.27/ 0.71 for retention
time/area response
System performanceb:
S/N ratio at LLOQ Z35 Z25
Autosampler carry-overc:
Blank plasma area response r9.74 (r1.33%
of LLOQ response)
r7.64 (r1.41%
of LLOQ response)
Method ruggednessd:
Precision (% CV) 0.75–1.19 0.68–1.83
Accuracy (%) Within 98.6–101.7 Within 98.2–102.1
Dilution reliabilitye:
Precision (% CV) 0.65–0.96 0.72–1.13
Accuracy (%) Within 99.1–100.8 Within 98.8–100.7
aAqueous standard mixture of analytes [at upper limit of quantitation (ULOQ)] and ISs injected as six consecutive injections at the start of each
batch.
bOne extracted blank (without analytes and ISs) and one extracted lower limit of quantitation (LLOQ) sample with ISs at the beginning of each
analytical batch.
cSamples injection sequence: extracted blank plasma-ULOQ-two extracted blank plasma samples-LLOQ-extracted blank plasma.
dOne QC batch analyzed on two BEH C18 columns with different batch numbers, while the second batch was analyzed by different analysts.
eBlank human plasma spiked with 1/5th and 1/10th dilution of the stock solution prepared at 2000/1000 ng/mL for cilostazol/3,4-dehydro cilostazol.
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human volunteers was also checked. This included paracetamol,
chlorpheniramine maleate, diclofenac, caffeine, acetylsalicylic acid
and ibuprofen. Their stock solutions (100 mg/mL) were prepared by
dissolving requisite amount in methanol:water (50:50, v/v). Further,
working solutions were prepared in the mobile phase and 10 mL was
injected to check for any possible interference at the retention time of
analytes and ISs.
For linearity of the method, ﬁve calibration curves were plotted
covering the range of 0.5–1000 ng/mL for CIL and 0.5–500 ng/mL for
DCIL using least square regression and 1/x2 as a weighting factor. The
area response ratio for analyte/IS obtained from multiple reaction
monitoring was used for regression analysis. The acceptance criterion
for a calibration curve was a correlation coefﬁcient (r2)Z0.99 and the
lowest standard on the calibration curve was accepted as the assay
sensitivity expressed as LLOQ.
Intra-batch accuracy and precision were determined by analyzing six
replicates of QC samples along with calibration curve standards on the
same day, while the inter-batch accuracy and precision were assessed
by analyzing ﬁve precision and accuracy batches on three consecutive
days. The precision (% CV) at each concentration level from the
nominal concentration was expected to be not greater than 15% and the
accuracy to be within 715% as per US FDA guidelines [16],
except for the LLOQ where it could be 80–120% of the nominalconcentration. Reinjection reproducibility was also checked by re-
injecting one entire validation batch.
Ion suppression/enhancement effect was studied through post
column analyte infusion experiment as described previously [17].
Brieﬂy, standard solutions containing the analytes (at ULOQ level) and
ISs were infused post column via a ‘T’ connector into the mobile
phase. Suitable aliquots of extracted blank plasma (10 mL) were then
injected into the column and MRM chromatograms were acquired for
analytes and ISs to check any possible interference due to endogenous
and exogenous plasma components.
The extraction recovery for the analytes and ISs was calculated by
comparing the mean area response of samples (n¼6) spiked before
extraction to that of extracts with post-spiked samples (spiked after
extraction) at four QC levels. Matrix effect, expressed as matrix factors
(MFs), was assessed by comparing the mean area response of post-
spiked samples with samples prepared in mobile phase. IS-normalized
MFs (analyte/IS) were calculated to access the variability of the assay
due to matrix effects. Relative matrix effect was assessed from the
precision (% CV) values of the slopes of the calibration curves
prepared from eight plasma lots, which included haemolysed and
lipemic plasma samples. To prove the absence of matrix interference,
% CV should not be greater than 3–4% [18].
Stability tests were conducted for stock solutions of analytes and ISs
for short term and long term stability at 25 and 5 1C, respectively. All
N.M. Bhatt et al.4stability results for spiked plasma samples were evaluated by measur-
ing the area response ratio (analyte/IS) of stability samples against
freshly prepared comparison standards. QC samples at HQC and LQC
levels were prepared to check for bench top, wet extract (autosampler),
processed sample, dry extract, freeze–thaw (20 and 70 1C) and
long term (20 and 70 1C) stabilities. The acceptance criterion was
710.0% deviation (from the nominal value) for stock solutions and
715.0% deviation for all other storage conditions.
2.6. Application to a bioequivalence study
The bioequivalence study was done with a test (100 mg cilostazol
tablets from Aché Laboratórios Farmaceuticos, Brazil) and a
reference formulation (Cebralats, Libbs Pharmaceuticals, Ltd.,
Brazil) in 30 healthy male subjects with a washout period of 10
days between dosing. The inclusion criteria for subject selection
were based on the age (18–40 years), mean weight of 63 kg, body
mass index (between 18.5 and 30.0 kg/height2), general physical
examination and vital signs (blood pressure, pulse rate, respiration
rate and oral temperature), electrocardiogram and laboratory tests
like hematology, blood chemistry, urine examination and immu-
nological tests. The exclusion criteria included allergic responses
to CIL, volunteers with history of alcoholism, smoking and having
a disease which may compromise the haemopoietic, gastrointest-
inal, renal, hepatic, cardiovascular, respiratory, central nervous
systems, or any other body system as well as diabetes, psychosis.Fig. 1 Product ion mass spectra in the positive ionization mode for (A) cilosThe study was conducted as per the International Conference on
Harmonization and US FDA guidelines [19]. The subjects were
informed about the objectives and possible risks involved in the
study and a written consent was obtained. The subjects were orally
administered a single dose of test and reference formulations with
240 mL of water. Blood samples were collected at 0.00 (pre-
dosing), 0.50, 1.00, 1.50, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00,
4.50, 5.00, 6.00, 8.00, 10.0, 12.0, 14.0, 16.0, 18.0, 20.0, 24.0, 36.0,
48.0 and 72.0 h after oral administration of the dose for test and
reference formulations in labeled K3EDTA-vacuettes. Plasma was
separated by centrifugation and kept frozen at 70 1C until analysis.
During study, subjects had a standard diet while water intake
was unmonitored. For the purpose of bioequivalence analysis, Cmax,
AUC0–72 h and AUC0–inf were considered as primary variables. The
pharmacokinetic parameters of CIL and DCIL were estimated by non-
compartmental analysis using WinNonlins software version 5.3
(Pharsight Corporation, Sunnyvale, CA, USA).3. Results and discussion
3.1. UPLC−MS/MS method development
Although there are several methods available in the literature for
the simultaneous determination of CIL and DCIL, they have a
limitation either in terms of sensitivity [7,9,11–14], overalltazol (m/z 370.3-288.3) and (B) cilostazol-d11, IS (m/z 381.2-288.3).
Fig. 2 Product ion mass spectra in the positive ionization mode for (A) 3,4-dehydro cilostazol (m/z 368.2-286.3) and (B) 3,4-dehydro cilostazol-d11,
IS (m/z 379.2-286.2).
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cumbersome extraction procedure [7–9]. Thus, the aim of the work
was to develop a rugged UPLC−MS/MS method which offered
combined advantage of sensitivity, selectivity, simplicity of
extraction procedure and high throughput. Unlike all previous
methods, deuterated internal standards were used, which could
adequately compensate for any variability during extraction and
analysis, thereby ensuring the accuracy of the generated data.
UPLC could provide a superior alternative to HPLC, especially in
reducing the analysis time when large numbers of samples were to
be analyzed in a clinical setting. This technology was capable of
achieving higher peak capacity, speed and sensitivity than
conventional HPLC. In addition, solvent consumption could be
considerably reduced compared to conventional 4.6 mm id col-
umns [20]. Further, tandem mass spectrometric detection was
expected to provide improved limits of detection and selectivity in
the multiple reaction monitoring (MRM) mode.
As both the analytes and ISs possess easily ionizable amino
groups, electrospray ionization (ESI) in the positive ion mode was
used for MRM analyses. The tandem mass spectrometry parameters
were optimized to maximize the response for the analytes and ISs
(Supplementary Table 1). The Q1 MS full scan spectra showed
consistent and predominant protonated [MþH]þ precursor ions at m/z
370.3, 381.2, 368.2 and 379.2 for CIL, CIL-d11, DCIL and DCIL-
d11 respectively. The product ion mass spectra under the optimized
conditions for the analytes and ISs are presented in Figs. 1 and 2. Themost stable and consistent fragments ions for CIL, CIL-d11, DCIL
and DCIL-d11 were observed at m/z 288.3, 288.3, 286.3 and 286.2,
respectively, as a result of selective loss of cyclohexyl (deuterated for
ISs) moiety from the protonated precursor ions.
Several reports recommended combination of two extraction proce-
dures for selective extraction of CIL and its metabolites from
endogenous substances for improved recovery from human plasma
[7–9]. Out of the two procedures, one is liquid–liquid extraction (LLE)
as both the analytes are lipophilic in nature with LogD values of 3.30
and 3.38 for CIL and DCIL respectively. Akiyama et al. [7] proposed
combination of protein precipitation (PP) and LLE for CIL extraction
from plasma. Similarly, two other reports applied LLE ﬁrst followed by
SPE to obtain clear extracts for CIL and its metabolites [8,9]. Both these
methods required multiple steps to process the aqueous as well as
organic portions for improved recovery and precision. Nirogi et al. [10]
proposed a simpliﬁed approach with LLE using a mixture of diethyl
ether and dichloromethane; however, the recovery was comparatively
less (69–71%). Yeon et al. [13] employed ﬁltration of plasma samples
using a low protein binding membrane syringe ﬁlter after diluting the
samples with water. The recovery obtained for CIL by this approach
was quantitative; nevertheless, it required a pre-column for on-line
sample preparation. In the present study, several trials were carried out
with all three extraction techniques namely PP, LLE and SPE. PP was
tried out using methanol and acetonitrile as protein precipitants;
however, the recovery was low with high variability (40–65%) at
LLOQ and LQC levels for both the analytes. Further, LLE was tested
Table 2 Extraction recovery and matrix factor for cilostazol and 3,4-dehydro cilostazol.
Analyte QC level Area response (n¼6) Extraction recovery
(%) (B/A)
Matrix factor
A B C Analyte (A/C) IS IS-normalized
Cilostazol LQC 2277 2172 2219 95.4 (95.8)a 1.026 1.015 1.011
MQC-2 221,645 214,012 218,648 96.6 (95.1)a 1.014 0.988 1.026
MQC-1 589,972 570,485 585,478 96.7 (96.5)a 1.008 0.995 1.012
HQC 1,187,945 1,142,988 1,180,245 96.2 (96.4)a 1.007 1.002 1.005
3,4-dehydro cilostazol LQC 1628 1553 1585 95.4 (95.8)b 1.027 1.019 1.008
MQC-2 87,385 84,258 86,139 96.4 (96.3)b 1.014 0.995 1.019
MQC-1 220,174 210,452 215,681 95.6 (95.1)b 1.021 1.017 1.004
HQC 455,982 434,658 448,523 95.3 (95.2)b 1.017 1.007 1.010
A: mean area response of six replicates prepared by spiking in extracted blank plasma; B: mean area response of six replicates prepared by spiking
before extraction; C: mean area response of six replicates prepared by spiking in mobile phase (neat samples); n: number of replicates; IS: Internal
standard; LQC: low quality control; MQC: medium quality control; HQC: high quality control.
aValues for internal standard, cilostazol-d11.
bValues for internal standard, 3,4-dehydro cilostazol-d11.
Fig. 3 Representative chromatograms of cilostazol (m/z 370.3-288.3) and cilostazol-d11 (m/z 381.2-288.3) in (A) blank plasma, (B) analytes
at LLOQ and (C) real subject sample at Cmax after administration of 100 mg dose of cilostazol tablet.
N.M. Bhatt et al.6
Fig. 4 Representative chromatograms of 3,4-dehydro cilostazol (m/z 368.2-286.3) and 3,4-dehydro cilostazol-d11 (m/z 379.2-286.2) in (A)
blank plasma, (B) analytes at LLOQ and (C) real subject sample at Cmax after administration of 100 mg dose of cilostazol tablet.
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chloroform, n-hexane, TBME, alone and in combination under neutral
and alkaline conditions as suggested in the reported methods [7–11,14].
The results showed poor recovery (55–65%) in all most all the solvents
especially for LLOQ, LQC and MQC-2 samples. Thus, SPE was
carried out on LiChroSep DVB-HL cartridges (30 mg, 1 cc) to over-
come the problems encountered during PP and LLE. These cartridges
contain reversed phase functionalized polymeric sorbent that gives
adequate retention for basic, acidic and neutral compounds. The clear
samples with high efﬁciency were obtained by SPE under the optimum
conditions as shown in Table 2. Quantitative and precise recovery (95–
97%) was obtained across all QC levels for both the analytes.
A majority of the methods used acetonitrile–ammonium acetate
buffer as the mobile phase for chromatographic analysis of CIL and
its metabolites under gradient program with a very long analysis
time [8,9,11–13]. Tata et al. [12] used two HPLC columns in
tandem for improved chromatographic efﬁciency and resolution to
get quantitative recovery and overcome matrix interferences, while
Yeon et al. [13] set up an on-line triple column switching system
for removal of plasma proteins and sample enrichment. Both these
methods took unduly long time for separation of analytes under
gradient elution and thus might not be useful for high throughputanalysis. Besides, both of these methods required signiﬁcant
modiﬁcations to existing HPLC systems. Thus for optimum
separation of analytes, several chromatographic parameters were
investigated on Acquity UPLC BEH C18 (50 mm 2.1 mm,
1.7 mm) column, including the type of organic modiﬁer, buffer,
the concentration and pH of the buffer, and organic modiﬁer:buffer
ratio. Initial trials were conducted using acetonitrile/methanol as an
organic modiﬁer along with mobile phase additives like ammonium
formate and ammonium acetate in the pH range of 2.0–5.0. Based
on the primary outcomes, acetonitrile and ammonium formate were
chosen for further optimization based on peak shape and adequate
response. The sensitivity was signiﬁcantly increased in presence of
ammonium formate compared to ammonium acetate buffer with
about 1.5 time higher peak areas of CIL and DCIL. Further, the
organic modiﬁer:buffer ratio and pH of the buffer were optimized
for better resolution without compromising the response for the
analytes. Acetonitrile content of 80% at a ﬂow rate of 0.350 mL/
min ensured adequate retention and peak resolution between the
analytes. It was observed that the pH of the mobile phase inﬂuences
both the chromatographic elution of the compounds and the
formation of the [MþH]þ molecular ions. As both the analytes
and ISs are basic compounds, the use of slightly acidic solution
N.M. Bhatt et al.8favors ionization of the analytes in ESI by protonation of their basic
sites. A mobile phase pH of 5.0 ensured adequate response for the
analytes with high sensitivity. CIL and DCIL were baselineTable 3 Pharmacokinetic parameters (mean7SD) and comparison
parameters following oral administration of 100 mg cilostazol tablet fo
Analyte Parameter Test Reference
Cilostazol Cmax (ng/mL) 635.6786.2 623.3779.9
AUC0–72 h (h ng/mL) 8532.27587.1 8567.27613.4
AUC0–inf (h ng/mL) 8832.67714.3 8914.57749.4
Tmax (h) 2.3370.30 2.5270.27
t1/2 (h) 11.4070.35 11.4670.28
Kel (1/h) 0.06170.002 0.06170.001
V/F (L) 157.373.1 160.474.8
3,4-dehydro
cilostazol
Cmax (ng/mL) 115.2713.8 109.9711.3
AUC0–72 h (h ng/mL) 1553.87312.3 1579.17326.8
AUC0–inf (h ng/mL) 1695.17331.8 1727.87354.2
Tmax (h) 2.2470.37 2.4770.25
t1/2 (h) 11.2670.23 11.5370.44
Kel (1/h) 0.06270.002 0.06070.003
V/F (L) 868.1713.1 909.9716.7
CI: conﬁdence interval; CV: coefﬁcient of variation; Cmax: maximum plasm
curve from zero hour to 72 h; AUC0–inf: area under the plasma concentratio
plasma concentration; t1/2: half life of drug elimination during the terminal
standard deviation.
Fig. 5 Mean plasma concentration–time proﬁle of (A) cilostazol and
(B) 3,4-dehydro cilostazol after oral administration of test (100 mg
cilostazol tablets from Aché Laboratórios Farmacêuticos, Brazil) and
reference (Cebralats, 100 mg of cilostazol tablets from Libbs Phar-
maceuticals Ltd., Brazil) formulations to 30 healthy Indian subjects
under fasting condition.resolved within 1.2 min with a resolution factor of 1.13, using
acetonitrile–2.0 mM ammonium formate, pH 5.0 adjusted with
0.1% formic acid (80:20, v/v) as a mobile phase (Figs. 3 and 4).
The capacity factors and number of theoretical plates were 1.51 and
1936 for CIL and 1.23 and 1560 for DCIL, respectively. The
efﬁciency of sample cleanup and chromatography can be demon-
strated by ﬂat baseline, with negligible inﬂuence of endogenous
and exogenous plasma components at the retention time of the
analytes and ISs. To achieve the desired sensitivity with acceptable
accuracy and precision, separate ISs were used for the drug and its
active metabolite. Deuterated ISs used in the present work helped
to overcome any possible matrix effects, errors in sample prepara-
tion and quantitative measurements for reliable results.
3.2. Assay performance and selectivity
System suitability, system performance, and carry-over data
indicate acceptable assay performance of the method as shown
in Table 1. Both the analytes showed good linearity over their
speciﬁed range (r2Z0.9994). The reinjection reproducibility in the
measurement of retention times for the analytes, expressed as %
CV, was r0.81 for 100 injections on the same column. The limit
of detection (LOD) and LLOQ of the method were 0.17 and
0.50 ng/mL for both the analytes at a signal-to-noise ratio of Z10
and Z30, respectively (Table 1).
The selectivity of the method can be seen from Figs. 3 and 4 in
blank plasma spiked with ISs, analytes at LLOQ and subject
sample at Cmax, which show no direct interference due to
endogenous components at the retention of the analytes and ISs.
Additionally, none of the commonly used medications by human
volunteers interfered at their respective retention times.
3.3. Accuracy and precision, recovery and matrix factors
The intra-batch precision (% CV) ranged from 0.91% to 1.99%
and the accuracy was within 98.0–101.7% for both the analytes.of treatment ratios and 90% CIs of natural log (Ln)-transformed
rmulation in 30 healthy Indian subjects under fasting.
Ratio
(test/reference) (%)
90% CI
(lower–upper)
Power Intra subject
variation (CV, %)
102.0 97.3–106.6 0.9996 5.38
99.6 94.1–105.4 0.9994 6.74
99.1 92.8–105.5 0.9997 7.15
– – – –
– – – –
– – – –
– – – –
104.9 99.8–109.4 0.9993 4.86
98.4 93.7–103.8 0.9995 5.69
98.1 94.0–103.2 0.9999 4.62
– – – –
– – – –
– – – –
– – – –
a concentration; AUC0–72 h: area under the plasma concentration–time
n–time curve from zero hour to inﬁnity; Tmax: time point of maximum
phase; Kel: elimination rate constant; V/F: volume of distribution; SD:
Determination of cilostazol and its metabolite in plasma 9Likewise for inter-batch experiments, the precision varied from
0.99% to 2.79% and the accuracy was within 98.1–102.7%
(Supplementary Table 2). The extraction recovery and IS-
normalized MF for the analytes are presented in Table 2. The
mean extraction recovery varied from 95.4% to 96.7% for CIL and
95.3% to 96.4% for DCIL at all QC levels. As presence of
unmonitored, co-eluting compounds from the matrix can directly
impact the overall reliability of a validated method, it is recom-
mended to evaluate MFs to consider the matrix effect [21].
Additionally, it is required to check the matrix effect in lipemic
and haemolysed plasma samples together with normal K3EDTA
plasma. The IS-normalized MFs using stable-isotope labeled IS
should be close to unity due to similarities in the chemical
properties and elution behavior of the analytes and ISs. The IS-
normalized MFs ranged from 1.004 to 1.026 for both the analytes.
In addition, interferences due to endogenous plasma compo-
nents were also assessed by plotting calibration curves for eight
different batches of blank plasma lots. The coefﬁcient of variation
(% CV) of the slopes of calibration lines for relative matrix effect
in eight different plasma lots was 1.79 and 1.46 for CIL and DCIL,Table 4 Comparative assessment of chromatographic methods deve
Sr.
no.
Technique;
linear range
(ng/mL)
Extraction procedure;
plasma volume (mL);
internal standard; mean
extraction recovery (%)
Column; mobile phase; run
(min); ﬂow rate (mL/min)
1 HPLC;
25–2000
PP with ACN followed
by LLE; 1000; OPC-
13012; 74.1
mBondapak C18 RP
(300 mm 3.9 mm, 10 mm)
ACN–water (42:58); 16.0;
2a HPLC;
20–1200 for
all the
analytes
LLE followed by SPE;
1000; OPC-3930 and
OPC-13112; 99.6–
104.9 for all the
analytes
TSK-GEL ODS-80TM
(150 mm 4.6 mm, 5 mm);
elution with ACN–100 mM
buffer (10:90 and 60:40); 7
3b LC-MS/MS;
5.0–1200 for
all the
analytes
LLE followed by SPE;
500; OPC-3930; 88.2–
106.6 for all the
analytes
Supercosil LC-18-D8
(150 mm 4.6 mm, 5 mm);
elution with ACN–acetate b
(10:90 and 90:10); 17.5; 1.
4c LC-MS/MS;
5.0–2000 for
CIL and
5–400 for
DCIL
LLE; 500; mosapride;
71.5/69.2 for CIL/
DCIL
Inertsil C18 (150 mm 4.6
5 mm); ACN–5 mM acetate
(90:10); 2.5; 1.2
5 HPLC;
25–2000
Dilution followed by
ﬁltration through
protein binding
membrane syringe
ﬁlter; 240; NA; 98.9
Two Capcell Pak MF Ph-1
(20/35 mm 4.0/2.0 mm, 5
followed by one Capcell Pa
120 (250 mm 1.5 mm, 5 m
ACN–water (10:90 and 40:
1.0 and 0.150
6c UPLC−MS/
MS; 0.5–1000
for CIL and
0.5–500 for
DCIL
SPE; 100; CIL-d11,
DCIL-d11; 96.2/95.6
for CIL/DCIL
Waters Acquity BEH C18 c
2 mM ammonium formate–
(20:80), pH 5.0; 1.2; 0.35
ISR: incurred sample reanalysis; PP: protein precipitation; ACN: acetonit
extraction; NA: not available; PS: present study.
aCilostazol and its seven metabolites.
bCilostazol with its three metabolites.
cCilostazol with 3,4-dehydro cilostazol (DCIL).respectively (Supplementary Table 3). Furthermore, the extracts
obtained through SPE showed negligible matrix effect, which were
analyzed by the post column analyte infusion method. The results
conﬁrmed the absence of signal suppression or enhancement at the
retention time of the analytes and ISs (Supplementary Fig. 1).3.4. Stability, dilution reliability and method ruggedness
Stock solutions kept for short-term and long-term stability as well
as spiked plasma solutions showed no evidence of degradation
under all studied conditions. No signiﬁcant degradation was
observed for both the analytes during sample storage and any of
the processing steps during extraction. The detailed results for
stability studies are presented in Supplementary Table 4. The
precision values for method ruggedness on different BEH C18
(50 mm 2.1 mm, 1.7 mm) columns and with different analysts
were within 0.68–1.83%. The ability to dilute samples which could
be above the upper limit of the calibration range was validated by
analyzing six replicate samples containing 2000 ng/mL of CIL andloped for cilostazol and its metabolite(s) in human plasma.
time Maximum on-
column loading per
injection volume
(ng); organic solvent
consumption
(mL, approximate
value)
Application; matrix effect
study; ISR results
(% change)
Ref.
;
1.7
800; 25 Pharmacokinetic study
with 100 mg CIL in 12
healthy subjects; NA; NA
[7]
Gradient
acetate
5/55; 1.0
240; 43 NA; NA; NA [8]
Gradient
uffer
0
12; 28 NA; NA; NA [9]
mm,
buffer
400/80 for CIL/
DCIL; 7.0
Pharmacokinetic study
with 100 mg CIL in 6
healthy subjects; NA; NA
[10]
columns
mm)
k C18 UG
m);
60); 21;
480; 3.5 Pharmacokinetic study
with 100 mg oral dose of
CIL in 16 human subjects;
NA; NA
[13]
olumn;
ACN
10/5 for CIL/DCIL;
2.5
Bioequivalence study with
100 mg CIL in 30 healthy
subjects; Post-column
infusion study; within
712%
PS
rile; CIL: cilostazol; LLE: liquid–liquid extraction; SPE: solid phase
N.M. Bhatt et al.101000 ng/mL of DCIL after ﬁve-/ten-fold dilution, respectively. The
precision (% CV) values for dilution reliability were between 0.72
and 1.13 for both the dilutions (Table 1).
3.5. Application of the method in healthy subjects and incurred
sample reanalysis results
Fig. 5 shows the plasma concentration vs. time proﬁle for CIL and
DCIL under fasting condition. The results showed that the newly
developed analytical method had the required sensitivity to
characterize the absorption, distribution and elimination phases
of cilostazol following oral dosing. A similar study with 100 mg
dose of CIL was reported in six healthy Indian subjects [10].
However, the values for pharmacokinetic parameters were not
available for comparison. Table 3 summarizes the mean pharma-
cokinetic parameters after oral administration of 100 mg cilostazol
tablet formulation in 30 subjects. The Tmax, Cmax and AUC values
obtained for CIL in the present work were comparable with two
previous reports [13,22]. Further, no statistically signiﬁcant
differences were found between the two formulations in any
parameter. The ratios of mean log-transformed parameters (Cmax,
AUC0–72 h and AUC0–inf) and their 90% CIs were all within the
deﬁned bioequivalence range of 80–125% (Table 3). These
observations conﬁrm the bioequivalence of the test sample with
the reference product in terms of rate and extent of absorption.
The reproducibility of the assay was also proven by incurred sample
reanalysis (ISR), which was conducted by selection of 125 subject
samples in the vicinity of Cmax and in the elimination phase of the
pharmacokinetic proﬁle of CIL and DCIL. The ISR results are
represented in Supplementary Fig. 2. The % change for assay
reproducibility in 125 incurred samples was within 713% for both
the analytes, which was within the acceptance criterion of720% [23].
3.6. Comparison with reported methods
The proposed UPLC−MS/MS method for CIL and DCIL is the
most sensitive and rapid (analysis time for extraction and
chromatography) compared to all other procedures for the deter-
mination of either CIL alone or with DCIL in human plasma.
Compared with the two reported studies [8,10], the sensitivity
obtained is 10 folds higher for CIL and DCIL. The present method
employs small plasma volume (100 mL) for processing, which is at
least ﬁve times lower than that of the existing methods. The on-
column loading of CIL/DCIL at ULOQ was only 10/5 ng per
sample injection, which was also much less than that of other
procedures. Further, ISR study has been conducted for assay
reproducibility which is not presented in other methods. A detailed
comparison of the present method with reported procedures for
CIL and DCIL in human plasma is given in Table 4.4. Conclusion
The UPLC−MS/MS method for the simultaneous determination of
CIL and DCIL in human plasma was developed and fully validated as
per US FDA guidelines. The method offers several advantages over
reported procedures, in terms of high sensitivity, low sample require-
ments, relatively simple extraction procedure and short overall analysis
time. The efﬁciency of solid-phase extraction and a short chromato-
graphic run time are highly favorable for high-throughput bioanalysis.
Absence of matrix interference is effectively shown by post-column
infusion and by the precision values for the slopes of calibration curves.The method is highly reproducible and is successfully used in the
analysis of about 1500 samples in a clinical setting.
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